215 related articles for article (PubMed ID: 36206041)
21. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
De SK
Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
[TBL] [Abstract][Full Text] [Related]
22. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
23. Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy.
Scheiter A; Keil F; Lüke F; Grosse J; Verloh N; Opitz S; Schlosser S; Kandulski A; Pukrop T; Dietmaier W; Evert M; Calvisi DF; Utpatel K
Curr Oncol; 2021 Mar; 28(2):1161-1169. PubMed ID: 33800328
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma.
Gong X; Akil A; Ndi A; Ji T; Liu X; Lovern M; Chen X
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1784-1794. PubMed ID: 37969064
[TBL] [Abstract][Full Text] [Related]
25. Progression-Free Survival in Patients With Cholangiocarcinoma With or Without
Bibeau K; Féliz L; Lihou CF; Ren H; Abou-Alfa GK
JCO Precis Oncol; 2022 Apr; 6():e2100414. PubMed ID: 35544727
[TBL] [Abstract][Full Text] [Related]
26. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
27. Clinicogenomic Analysis of
Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.
Lim M; Lynch PT; Bai X; Hsiehchen D
JCO Precis Oncol; 2023 Jan; 7():e2200340. PubMed ID: 36634295
[No Abstract] [Full Text] [Related]
29. Pemigatinib Is Active in Some
Cancer Discov; 2020 May; 10(5):639. PubMed ID: 32245820
[TBL] [Abstract][Full Text] [Related]
30. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Mazzaferro V; El-Rayes BF; Droz Dit Busset M; Cotsoglou C; Harris WP; Damjanov N; Masi G; Rimassa L; Personeni N; Braiteh F; Zagonel V; Papadopoulos KP; Hall T; Wang Y; Schwartz B; Kazakin J; Bhoori S; de Braud F; Shaib WL
Br J Cancer; 2019 Jan; 120(2):165-171. PubMed ID: 30420614
[TBL] [Abstract][Full Text] [Related]
31. Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib.
Yukutake M; Sekito T; Yamakita I; Itakura H; Kabu K; Nagata S
Intern Med; 2023 Apr; 62(8):1151-1155. PubMed ID: 35945011
[TBL] [Abstract][Full Text] [Related]
32. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
Meric-Bernstam F; Hollebecque A; Furuse J; Oh DY; Bridgewater JA; Shimura M; Anderson B; Hangai N; Wacheck V; Goyal L
Clin Cancer Res; 2024 Apr; 30(8):1466-1477. PubMed ID: 38329716
[TBL] [Abstract][Full Text] [Related]
33. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
34. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
36. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
Huang C; Wen Q; Chen J; Zhong H; Xiang X; Xiong J; Deng J
Cancer Treat Res Commun; 2022; 31():100568. PubMed ID: 35477128
[TBL] [Abstract][Full Text] [Related]
37. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
38. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
40. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
Rengan AK; Denlinger CS
J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
